Additional Information
Book Details
Abstract
This issue of Medical Clinics of North America, guest edited by Robert E. Brannigan, MD, is devoted to Urology. Articles in this outstanding issue include: Prostate Cancer Screening; Treatment Modalities and Outcomes for Prostate Cancer; Kidney, Ureteral, and Bladder Cancer: A Primer for the Internist; Testicular Cancer: Epidemiology, Diagnosis, and Treatment; Urinary Stone Disease: Diagnosis, Medical Therapy, and Surgical Management; Male Voiding Dysfunction, BPH, and Urinary Retention; Female Voiding Dysfunction and Urinary Incontinence; Penile and Urethral Reconstructive Surgery; Male Infertility Diagnosis and Treatment in the Era of IVF/ICSI; Sexual Dysfunction: Behavioral, Medical, and Surgical Therapies; Hypogonadism: Therapeutic Risks, Benefits, and Outcomes; Cutaneous Diseases of the External Genitalia; Urological Emergencies; Telemedicine: Early Experience in the Urology Clinic; and Men’s Health Programs: The Intersection of Internal Medicine and Urology.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Urology | i | ||
| Copyright | ii | ||
| CME Accreditation Page | iii | ||
| PROGRAM OBJECTIVE | iii | ||
| TARGET AUDIENCE | iii | ||
| LEARNING OBJECTIVES | iii | ||
| ACCREDITATION | iii | ||
| DISCLOSURE OF CONFLICTS OF INTEREST | iii | ||
| UNAPPROVED/OFF-LABEL USE DISCLOSURE | iv | ||
| TO ENROLL | iv | ||
| METHOD OF PARTICIPATION | iv | ||
| CME INQUIRIES/SPECIAL NEEDS | iv | ||
| Contributors | vii | ||
| CONSULTING EDITOR | vii | ||
| EDITOR | vii | ||
| AUTHORS | vii | ||
| Contents | xi | ||
| Foreword: Go with the Flow | xi | ||
| Preface: Urology and Medicine | xi | ||
| Prostate Cancer Screening | xi | ||
| Prostate Cancer: A Contemporary Approach to Treatment and Outcomes | xi | ||
| Kidney, Ureteral, and Bladder Cancer: A Primer for the Internist | xi | ||
| Testicular Cancer: Epidemiology, Diagnosis, and Management | xi | ||
| Urinary Stone Disease: Diagnosis, Medical Therapy, and Surgical Management | xii | ||
| Cutaneous Lesions of the External Genitalia | xii | ||
| Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia, and Urinary Retention | xii | ||
| Female Voiding Dysfunction and Urinary Incontinence | xii | ||
| Penile and Urethral Reconstructive Surgery | xiii | ||
| Male Infertility Diagnosis and Treatment in the Era of In Vitro Fertilization and Intracytoplasmic Sperm Injection | xiii | ||
| Sexual Dysfunction: Behavioral, Medical, and Surgical Treatment | xiii | ||
| Hypogonadism: Therapeutic Risks, Benefits, and Outcomes | xiii | ||
| Urologic Emergencies | xiii | ||
| The Current State of Telemedicine in Urology | xiv | ||
| The Intersection of Medicine and Urology: An Emerging Paradigm of Sexual Function, Cardiometabolic Risk, Bone Health, and M ... | xiv | ||
| Go with the Flow | xv | ||
| REFERENCE | xvi | ||
| Urology and Medicine | xvii | ||
| REFERENCES | xix | ||
| Prostate Cancer Screening | 199 | ||
| Key points | 199 | ||
| INTRODUCTION | 200 | ||
| THE PRE–PROSTATE-SPECIFIC ANTIGEN SCREENING ERA | 200 | ||
| Prostate-Specific Antigen as a First-Line Screening Test | 200 | ||
| Randomized Clinical Trials of Prostate-Specific Antigen Screening | 200 | ||
| US Food and Drug Administration Approval of Prostate-Specific Antigen as an Aid to the Early Detection of Prostate-Specific ... | 201 | ||
| THE PROSTATE-SPECIFIC ANTIGEN SCREENING ERA (1991–2008) | 201 | ||
| Epidemiologic Impact of Prostate-Specific Antigen Screening | 201 | ||
| Enhancements of Prostate-Specific Antigen Tests to Increase Specificity | 201 | ||
| Prostate-specific antigen velocity | 201 | ||
| Prostate-specific antigen velocity risk count | 202 | ||
| Prostate-specific antigen density | 202 | ||
| Age-specific median prostate-specific antigen values | 202 | ||
| Free-to-total prostate-specific antigen | 202 | ||
| Prostate health index | 202 | ||
| The 4KScore | 203 | ||
| Concerns About Prostate-Specific Antigen Screening | 203 | ||
| Politics of Prostate-Specific Antigen Testing: The US Preventive Services Task Force | 203 | ||
| 2008 TO 2017: THE PROSTATE-SPECIFIC ANTIGEN PROHIBITION ERA | 204 | ||
| Criticisms of US Preventive Services Task Force Analysis | 204 | ||
| Psychological Effects | 206 | ||
| EPILOGUE: 2017 CANCER INTERVENTION AND SURVEILLANCE MODELING NETWORK REANALYSIS OF PROSTATE, LUNG, COLORECTAL, AND OVARIAN ... | 206 | ||
| 2017—THE FUTURE: PROSTATE-SPECIFIC ANTIGEN SCREENING RENAISSANCE | 206 | ||
| US Preventive Services Task Force Backs Away from Total Ban on Prostate-Specific Antigen Testing | 206 | ||
| The Burden of Prostate-Specific Antigen–Based Prostate Cancer in the Future | 207 | ||
| Author’s Recommendations for Prostate-Specific Antigen Testing | 207 | ||
| Prostate Cancer Screening Renaissance | 208 | ||
| ACKNOWLEDGMENTS | 208 | ||
| REFERENCES | 208 | ||
| Prostate Cancer | 215 | ||
| Key points | 215 | ||
| INTRODUCTION | 215 | ||
| OBSERVATION | 216 | ||
| Watchful Waiting: Treatment Only for Symptomatic Relief | 216 | ||
| Active Surveillance: Disease Monitoring with Treatment on Progression or Patient Preference | 217 | ||
| RADICAL PROSTATECTOMY | 218 | ||
| Surgery and Oncologic Outcomes | 218 | ||
| The Adverse Effects of Surgery | 219 | ||
| Lymph Node Dissection During Radical Prostatectomy | 219 | ||
| Open Versus Robotic Radical Prostatectomy | 219 | ||
| Disease Monitoring and Salvage Treatment Following Surgery | 220 | ||
| RADIOTHERAPY | 220 | ||
| External Beam Radiotherapy | 221 | ||
| Brachytherapy | 221 | ||
| Adverse Effects of Radiotherapy | 221 | ||
| Disease Monitoring and Salvage Treatment Following Radiotherapy | 222 | ||
| ANDROGEN DEPRIVATION THERAPY AND OTHER SYSTEMIC THERAPIES | 222 | ||
| The Basics of Androgen Deprivation Therapy | 222 | ||
| The Adverse Effects of Androgen Deprivation Therapy | 223 | ||
| Second-Generation Androgen Deprivation Therapy | 223 | ||
| Chemotherapy for Prostate Cancer | 223 | ||
| Immunotherapy for Prostate Cancer | 224 | ||
| Bisphosphonates for Patients with Bone Metastases | 224 | ||
| FUTURE CONSIDERATIONS | 224 | ||
| REFERENCES | 224 | ||
| Kidney, Ureteral, and Bladder Cancer | 231 | ||
| Key points | 231 | ||
| INTRODUCTION | 231 | ||
| KIDNEY CANCER: RENAL CELL CARCINOMA | 232 | ||
| Patient History | 232 | ||
| Pathophysiology | 232 | ||
| Physical Examination | 233 | ||
| Diagnostic Testing and Imaging Studies | 233 | ||
| Differential Diagnosis | 236 | ||
| Treatment | 236 | ||
| UPPER URINARY TRACT AND BLADDER CANCER: UROTHELIAL CARCINOMA | 238 | ||
| Patient History | 239 | ||
| Pathophysiology | 239 | ||
| Physical Examination | 240 | ||
| Diagnostic Testing and Imaging | 240 | ||
| Differential Diagnosis | 241 | ||
| Treatment of Bladder Urothelial Carcinoma | 243 | ||
| Treatment of Upper Tract Urothelial Carcinoma | 243 | ||
| SUMMARY | 244 | ||
| REFERENCES | 244 | ||
| Testicular Cancer | 251 | ||
| Key points | 251 | ||
| INTRODUCTION AND EPIDEMIOLOGY | 251 | ||
| CAUSE AND RISK FACTORS | 251 | ||
| SYMPTOMS AND PRESENTATION | 252 | ||
| DIAGNOSTIC TESTS | 252 | ||
| DIFFERENTIAL DIAGNOSIS | 253 | ||
| STAGING | 253 | ||
| PATHOLOGY | 253 | ||
| Germ Cell Tumors | 253 | ||
| Intratubular germ cell neoplasia | 253 | ||
| Seminoma | 254 | ||
| Nonseminoma | 256 | ||
| Gonadal Stromal Tumors | 256 | ||
| Leydig cell and Sertoli cell | 256 | ||
| Granulosa cell | 256 | ||
| Other Tumors | 257 | ||
| Lymphoma | 257 | ||
| Gonadoblastoma | 257 | ||
| INITIAL MANAGEMENT OF A TESTICULAR MASS | 257 | ||
| General Considerations | 257 | ||
| Fertility Considerations | 257 | ||
| Radical Orchiectomy | 257 | ||
| SEMINOMA: CLINICAL STAGE IA OR IB | 258 | ||
| SEMINOMA: CLINICAL STAGE IIA, IIB, OR IS | 258 | ||
| SEMINOMA: CLINICAL STAGE IIC OR III | 259 | ||
| NONSEMINOMATOUS GERM CELL TUMOR: CLINICAL STAGE IA/IB | 259 | ||
| NONSEMINOMATOUS GERM CELL TUMOR: CLINICAL STAGE IS | 260 | ||
| NONSEMINOMATOUS GERM CELL TUMOR: CLINICAL STAGE IIA OR IIB | 260 | ||
| NONSEMINOMATOUS GERM CELL TUMOR: CS IIC OR III | 261 | ||
| NONSEMINOMATOUS GERM CELL TUMOR: MANAGEMENT OF POSTCHEMOTHERAPY RECURRENCE | 261 | ||
| NONSEMINOMATOUS GERM CELL TUMOR: SALVAGE SETTINGS | 261 | ||
| Salvage Chemotherapy | 261 | ||
| Desperation Retroperitoneal Lymph Node Dissection | 261 | ||
| LATE RELAPSES | 262 | ||
| TREATMENT-RELATED SEQUELAE | 262 | ||
| SUMMARY | 262 | ||
| REFERENCES | 262 | ||
| Urinary Stone Disease | 265 | ||
| Key points | 265 | ||
| INTRODUCTION | 265 | ||
| DIAGNOSIS | 266 | ||
| Presentation | 266 | ||
| Clinical Evaluation | 266 | ||
| Imaging | 266 | ||
| Computed tomography | 266 | ||
| Ultrasound | 266 | ||
| MRI | 267 | ||
| Laboratory Evaluation | 267 | ||
| DIETARY AND MEDICAL THERAPY | 267 | ||
| Medical Expulsive Therapy for Ureteral Stones | 267 | ||
| Urine Volume | 268 | ||
| Calcium Stones | 268 | ||
| Dietary intervention | 268 | ||
| Thiazides | 268 | ||
| Citrate | 268 | ||
| Allopurinol | 269 | ||
| Uric Acid Stones | 269 | ||
| Cutaneous Lesions of the External Genitalia | 279 | ||
| Key points | 279 | ||
| INITIAL EVALUATION | 279 | ||
| GENITAL INVOLVEMENT OF SYSTEMIC SKIN DISEASES | 279 | ||
| Psoriasis | 280 | ||
| Lichen Planus | 280 | ||
| Lichen Sclerosus/Balanitis Xerotica Obliterans | 281 | ||
| Erythema Multiforme | 282 | ||
| Reactive Arthritis (Formerly Reiter Syndrome) | 282 | ||
| Fixed Drug Eruption | 282 | ||
| NONINFECTIOUS ULCERS | 283 | ||
| Behçet Disease | 283 | ||
| Pyoderma Gangrenosum | 284 | ||
| INFECTIOUS DISORDERS | 284 | ||
| Genital Herpes | 284 | ||
| Genital Warts/Human Papilloma Virus | 285 | ||
| Syphilis | 287 | ||
| Chancroid | 289 | ||
| Scabies | 289 | ||
| Molluscum Contagiosum | 290 | ||
| Balanitis and Balanoposthitis | 290 | ||
| Cellulitis and Erysipelas | 290 | ||
| Fournier Gangrene | 291 | ||
| Hidradenitis Suppurativa | 291 | ||
| NEOPLASTIC CONDITIONS | 292 | ||
| Squamous Cell Carcinoma In Situ/Bowen Disease | 292 | ||
| Bowenoid Papulosis | 292 | ||
| Squamous Cell Carcinoma | 294 | ||
| Verrucous Carcinoma (Buschke-Lowenstein Tumor) | 294 | ||
| Kaposi Sarcoma | 295 | ||
| Extramammary Paget Disease | 296 | ||
| MISCELLANEOUS BENIGN CONDITIONS | 296 | ||
| Angiokeratoma of Fordyce | 296 | ||
| Pearly Penile Papules | 297 | ||
| Zoon Balanitis/Vulvitis | 297 | ||
| Median Raphe Cyst | 297 | ||
| Epidermoid Cyst | 298 | ||
| Vitiligo | 298 | ||
| REFERENCES | 298 | ||
| Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia, and Urinary Retention | 301 | ||
| Key points | 301 | ||
| INTRODUCTION | 301 | ||
| VOIDING DYSFUNCTION | 302 | ||
| VOIDING DYSFUNCTION AND BENIGN PROSTATIC HYPERPLASIA | 302 | ||
| BENIGN PROSTATIC HYPERPLASIA AND URINARY RETENTION | 303 | ||
| Acute Urinary Retention | 303 | ||
| CHRONIC URINARY RETENTION | 303 | ||
| DIAGNOSIS OF VOIDING DYSFUNCTION | 303 | ||
| History and Patient-Specific Questionnaires | 304 | ||
| Physical Examination | 304 | ||
| Laboratory Testing | 304 | ||
| Urinalysis | 304 | ||
| DIFFERENTIAL DIAGNOSIS | 304 | ||
| Infectious Cause | 304 | ||
| Obstruction | 305 | ||
| Inflammation | 305 | ||
| Neoplasm | 306 | ||
| Metabolic | 306 | ||
| Medication-Induced | 306 | ||
| Neurologic | 306 | ||
| TREATMENT | 306 | ||
| Watchful Waiting | 306 | ||
| Medical Therapy | 307 | ||
| Phytotherapy | 307 | ||
| Alpha-Blockers | 307 | ||
| 5-Alpha Reductase Inhibitors | 307 | ||
| Phosphodiesterase 5 Inhibitors | 308 | ||
| Antimuscarinics | 308 | ||
| Combination Therapy | 308 | ||
| MANAGEMENT | 308 | ||
| REFERENCES | 309 | ||
| Female Voiding Dysfunction and Urinary Incontinence | 313 | ||
| Key points | 313 | ||
| NORMAL URINARY CONTINENCE AND VOIDING | 313 | ||
| Lower Urinary Health Across the Lifespan in Women | 314 | ||
| Urodynamics | 314 | ||
| OVERACTIVE BLADDER | 314 | ||
| Epidemiology and Impact | 315 | ||
| Initial Evaluation: Patient History, Symptoms, and Physical Examination | 315 | ||
| Diagnostic testing and imaging | 316 | ||
| Management goals | 316 | ||
| First-line treatment: behavioral therapies | 316 | ||
| Second-line treatment: pharmacologic management | 316 | ||
| Third-line treatment: surgical management | 317 | ||
| STRESS URINARY INCONTINENCE | 317 | ||
| Epidemiology and Impact | 317 | ||
| Initial evaluation: patient history, symptoms, and physical examination | 318 | ||
| Diagnostic Testing and Imaging | 318 | ||
| Management Goals | 318 | ||
| Nonsurgical, Conservative Therapies | 318 | ||
| Surgical Treatment | 319 | ||
| VESICOVAGINAL AND URETEROVAGINAL FISTULAS | 319 | ||
| Epidemiology and Impact | 320 | ||
| Initial Evaluation: Patient History, Symptoms, and Physical Examination | 320 | ||
| Treatment of Fistulas | 320 | ||
| SUMMARY | 321 | ||
| REFERENCES | 321 | ||
| Penile and Urethral Reconstructive Surgery | 325 | ||
| Key points | 325 | ||
| INTRODUCTION | 325 | ||
| URETHRAL DILATION AND DIRECT VISION INTERNAL URETHROTOMY | 326 | ||
| Indications/Contraindications | 326 | ||
| Patient Preparation | 327 | ||
| Approach | 327 | ||
| Postprocedure Care | 328 | ||
| Reducing Complications | 328 | ||
| Outcomes and Evidence | 328 | ||
| URETHROPLASTY | 328 | ||
| Indications/Contraindications | 328 | ||
| Patient Preparation | 329 | ||
| Approach | 329 | ||
| Postprocedure Care | 330 | ||
| Reducing Complications | 330 | ||
| Outcomes | 330 | ||
| ARTIFICIAL URINARY SPHINCTER IMPLANTATION | 331 | ||
| Indications/Contraindications | 331 | ||
| Patient Preparation | 331 | ||
| Approach | 331 | ||
| Postprocedure Care | 332 | ||
| Reducing Complications | 332 | ||
| Reported Outcomes | 332 | ||
| SUMMARY | 333 | ||
| REFERENCES | 333 | ||
| Male Infertility Diagnosis and Treatment in the Era of In Vitro Fertilization and Intracytoplasmic Sperm Injection | 337 | ||
| Key points | 337 | ||
| INTRODUCTION | 337 | ||
| EVALUATION | 338 | ||
| History | 338 | ||
| Physical Examination | 339 | ||
| Hormonal Evaluation | 339 | ||
| Semen Analysis | 340 | ||
| Imaging | 341 | ||
| TREATMENT | 342 | ||
| Medical | 342 | ||
| Surgical | 342 | ||
| Assisted Reproductive Technologies | 343 | ||
| FUTURE CONSIDERATIONS AND SUMMARY | 344 | ||
| REFERENCES | 344 | ||
| Sexual Dysfunction | 349 | ||
| Key points | 349 | ||
| INTRODUCTION | 349 | ||
| NONPHARMACOLOGIC TREATMENT OPTIONS | 349 | ||
| Diet | 350 | ||
| Exercise and Physical Activity | 351 | ||
| Medication Adjustment | 351 | ||
| Tobacco, Alcohol, and Marijuana Use | 351 | ||
| PHARMACOLOGIC TREATMENT OPTIONS | 352 | ||
| Over-the-Counter and Herbal Supplements | 352 | ||
| Arginine | 352 | ||
| Ginseng | 352 | ||
| Horny goat weed | 352 | ||
| Ginkgo biloba | 352 | ||
| Phosphodiesterase Type 5 Inhibitors | 352 | ||
| Mechanism/pharmacokinetics | 353 | ||
| Optimization of use | 353 | ||
| Contraindications | 353 | ||
| Adverse events | 354 | ||
| Vacuum Erection Device | 354 | ||
| Intraurethral Suppository | 354 | ||
| Intracavernosal (Penile) Injection Therapy | 354 | ||
| Adverse events/side effects/contraindications | 355 | ||
| SURGICAL TREATMENT OPTIONS | 355 | ||
| Noninflatable Implants (Malleable or Semirigid) | 355 | ||
| Two-Piece Inflatable Implant | 356 | ||
| Three-Piece Inflatable Implant | 356 | ||
| Complications of penile prosthesis use | 356 | ||
| REFERENCES | 357 | ||
| Hypogonadism | 361 | ||
| Key points | 361 | ||
| INTRODUCTION | 361 | ||
| DIAGNOSIS OF HYPOGONADISM | 362 | ||
| TREATMENT OF HYPOGONADISM | 364 | ||
| TESTOSTERONE THERAPY AND CARDIOVASCULAR RISK | 366 | ||
| SUMMARY | 368 | ||
| REFERENCES | 368 | ||
| Urologic Emergencies | 373 | ||
| Key points | 373 | ||
| ACUTE URINARY RETENTION | 373 | ||
| Clinical Presentation | 373 | ||
| Diagnosis | 374 | ||
| Treatment | 374 | ||
| NEPHROLITHIASIS | 375 | ||
| Clinical Presentation | 375 | ||
| Diagnosis | 376 | ||
| Treatment | 376 | ||
| PENILE EMERGENCIES: PARAPHIMOSIS | 376 | ||
| Clinical Presentation | 376 | ||
| Diagnosis | 377 | ||
| Treatment | 377 | ||
| PENILE EMERGENCIES: PENILE FRACTURE | 377 | ||
| Clinical Presentation | 377 | ||
| Diagnosis | 378 | ||
| Treatment | 378 | ||
| PENILE EMERGENCIES: PRIAPISM | 379 | ||
| Clinical Presentation | 379 | ||
| Diagnosis | 380 | ||
| Treatment | 380 | ||
| SCROTAL EMERGENCIES: FOURNIER GANGRENE | 381 | ||
| Clinical Presentation | 381 | ||
| Diagnosis | 381 | ||
| Treatment | 382 | ||
| SCROTAL EMERGENCIES: TESTICULAR TORSION | 382 | ||
| Clinical Presentation | 382 | ||
| Diagnosis | 383 | ||
| Treatment | 383 | ||
| REFERENCES | 383 | ||
| The Current State of Telemedicine in Urology | 387 | ||
| Key points | 387 | ||
| INTRODUCTION | 387 | ||
| CURRENT USE OF TELEMEDICINE | 388 | ||
| NECESSARY SYSTEMS AND PROCEDURES | 388 | ||
| TECHNIQUES/TYPES OF SERVICES | 389 | ||
| Video Visits | 389 | ||
| Online Services | 391 | ||
| Electronic Consults | 391 | ||
| Tele-Rounding | 391 | ||
| Tele-Monitoring | 393 | ||
| Tele-Mentoring, Tele-Proctoring, and Education | 393 | ||
| Tele-Simulation | 393 | ||
| REIMBURSEMENT | 394 | ||
| TELEMEDICINE IN PRACTICE | 394 | ||
| CHALLENGES/LIMITATIONS | 395 | ||
| FUTURE CONSIDERATIONS/SUMMARY | 396 | ||
| REFERENCES | 396 | ||
| The Intersection of Medicine and Urology | 399 | ||
| Key points | 399 | ||
| WHY MEN’S HEALTH? | 400 | ||
| WHO IS THE MEN’S HEALTH DOCTOR: PRIMARY CARE PHYSICIAN, UROLOGIST, OR SUBSPECIALIST? | 400 | ||
| ERECTILE DYSFUNCTION AND SUBCLINICAL CARDIOVASCULAR DISEASE: AN INTERSECTION OF MEDICINE AND UROLOGY | 401 | ||
| THE TEMPORAL RELATIONSHIP OF ERECTILE DYSFUNCTION, SUBCLINICAL CARDIOVASCULAR DISEASE, AND CLINICAL CARDIOVASCULAR DISEASE | 401 | ||
| RECOMMENDATIONS FOR EVALUATION OF CARDIOVASCULAR RISK IN MEN WITH ERECTILE DYSFUNCTION | 402 | ||
| AN UPDATE ON TESTOSTERONE REPLACEMENT THERAPY AS ANOTHER EXAMPLE OF THE POTENTIAL OF THE MEN’S HEALTH CENTER | 404 | ||
| CHANGES TO THE FOOD AND DRUG ADMINISTRATION LABEL | 404 | ||
| STATUS OF PUBLISHED STUDIES LEADING TO ADDITION OF CARDIOVASCULAR RISK WARNING | 404 | ||
| REVIEW OF NEW CARDIOVASCULAR STUDIES | 405 | ||
| SUMMARY OF CARDIOVASCULAR STUDIES BECAUSE FOOD AND DRUG ADMINISTRATION LABEL CHANGE | 406 | ||
| FINAL EXAMPLE OF THE POTENTIAL OF THE MEN’S HEALTH CENTER: OSTEOPOROSIS IS A MEN’S HEALTH CONCERN: INCIDENCE AND GENDER DIS ... | 406 | ||
| GAPS IN TREATMENT IN MALE OSTEOPOROSIS ARE SIGNIFICANT | 407 | ||
| THE COMPONENTS OF A MEN’S HEALTH CURRICULUM: AN OUTGROWTH OF THE MEN’S HEALTH CENTER | 408 | ||
| BUILDING A MEN’S HEALTH CENTER | 409 | ||
| THE FUTURE OF MEN’S HEALTH | 409 | ||
| REFERENCES | 410 |